Skip to main content
Journal cover image

Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.

Publication ,  Journal Article
McManus, HD; Zhang, D; Schwartz, FR; Wu, Y; Infield, J; Ho, E; Armstrong, AJ; George, DJ; Kruse, D; Gupta, RT; Harrison, MR
Published in: Clin Genitourin Cancer
December 2023

INTRODUCTION: Biomarkers are needed to identify patients with metastatic renal cell carcinoma (mRCC) most likely to benefit from immune checkpoint inhibitors. We examined associations between radiographically assessed body composition (BC) variables and body mass index (BMI) with clinical outcomes for patients with mRCC receiving first-line ipilimumab + nivolumab (ipi/nivo). PATIENTS AND METHODS: We retrospectively reviewed all patients with mRCC treated with first-line ipi/nivo at one institution before June 1, 2021 with an analyzable baseline computed tomography (CT) scan. BC variables (skeletal muscle index [SMI], subcutaneous adipose tissue index [SATI], and visceral adipose tissue index [VATI]) were measured using baseline CT scans. Relationships between BC variables and clinical outcomes were examined using Cox proportional hazard regression models. RESULTS: Ninety-nine patients were analyzed (74% male, 64% overweight/obese, 75% low SMI). Controlling for age, IMDC risk, and sex (for BMI analyses), high vs. low SMI (HR=2.433, CI: 1.397-4.238, P=.0017), high vs. low SATI (HR=1.641, CI: 1.023-2.632, P=.0398), and obese BMI (≥ 30 kg/m2) vs. normal/overweight BMI (<30 kg/m2) (HR=1.859, CI: 1.156-2.989, P=.0105) were significantly associated with progression-free survival (PFS). Median overall survival (OS) for low SMI patients was higher (42.74 months, CI: 26.84, NR) than median OS for high SMI patients (27.01 months, CI: 15.28, NR) (adjusted HR=1.728, CI: 0.909-3.285, P=.0952). No BC variables were significantly associated with OS or objective response rate. CONCLUSIONS: Low SMI and low SATI were associated with significantly better PFS for patients with mRCC receiving first-line ipi/nivo. Radiographic BC variables may be useful prognostic biomarkers in this setting.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Genitourin Cancer

DOI

EISSN

1938-0682

Publication Date

December 2023

Volume

21

Issue

6

Start / End Page

e429 / e437.e2

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Overweight
  • Oncology & Carcinogenesis
  • Obesity
  • Nivolumab
  • Male
  • Kidney Neoplasms
  • Ipilimumab
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McManus, H. D., Zhang, D., Schwartz, F. R., Wu, Y., Infield, J., Ho, E., … Harrison, M. R. (2023). Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab. Clin Genitourin Cancer, 21(6), e429-e437.e2. https://doi.org/10.1016/j.clgc.2023.05.006
McManus, Hannah D., Dylan Zhang, Fides R. Schwartz, Yuan Wu, Jordan Infield, Ethan Ho, Andrew J. Armstrong, et al. “Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.Clin Genitourin Cancer 21, no. 6 (December 2023): e429-e437.e2. https://doi.org/10.1016/j.clgc.2023.05.006.
McManus HD, Zhang D, Schwartz FR, Wu Y, Infield J, Ho E, et al. Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab. Clin Genitourin Cancer. 2023 Dec;21(6):e429-e437.e2.
McManus, Hannah D., et al. “Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.Clin Genitourin Cancer, vol. 21, no. 6, Dec. 2023, pp. e429-e437.e2. Pubmed, doi:10.1016/j.clgc.2023.05.006.
McManus HD, Zhang D, Schwartz FR, Wu Y, Infield J, Ho E, Armstrong AJ, George DJ, Kruse D, Gupta RT, Harrison MR. Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab. Clin Genitourin Cancer. 2023 Dec;21(6):e429-e437.e2.
Journal cover image

Published In

Clin Genitourin Cancer

DOI

EISSN

1938-0682

Publication Date

December 2023

Volume

21

Issue

6

Start / End Page

e429 / e437.e2

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Overweight
  • Oncology & Carcinogenesis
  • Obesity
  • Nivolumab
  • Male
  • Kidney Neoplasms
  • Ipilimumab
  • Humans
  • Female